Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review

Freke R Zuure, Anouk T Urbanus, Miranda W Langendam, Charles W Helsper, Charlotte H S B van den Berg, Udi Davidovich, Maria Prins, Freke R Zuure, Anouk T Urbanus, Miranda W Langendam, Charles W Helsper, Charlotte H S B van den Berg, Udi Davidovich, Maria Prins

Abstract

Background: Effective screening programs are urgently needed to provide undiagnosed hepatitis C virus (HCV)-infected individuals with therapy. This systematic review of characteristics and outcomes of screening programs for HCV focuses on strategies to identify HCV risk groups hidden in the general population.

Methods: We conducted a comprehensive search of MEDLINE and EMBASE databases for articles published between 1991-2010, including studies that screened the general population using either a newly developed (nonintegrated) screening program or one integrated in existing health care facilities. Look-back studies, prevalence studies, and programs targeting high-risk groups in care (e.g., current drug users) were excluded.

Results: After reviewing 7052 studies, we identified 67 screening programs: 24 nonintegrated; 41 programs integrated in a variety of health care facilities (e.g., general practitioner); and 2 programs with both integrated and nonintegrated strategies. Together, these programs identified approximately 25,700 HCV-infected individuals. In general, higher HCV prevalence was found in programs in countries with intermediate to high HCV prevalence, in psychiatric clinics, and in programs that used a prescreening selection based on HCV risk factors. Only 6 programs used a comparison group for evaluation purposes, and 1 program used theory about effective promotion for screening. Comparison of the programs and their effectiveness was hampered by lack of reported data on program characteristics, clinical follow-up, and type of diagnostic test.

Conclusions: A prescreening selection based on risk factors can increase the efficiency of screening in low-prevalence populations, and we need programs with comparison groups to evaluate effectiveness. Also, program characteristics such as type of diagnostic test, screening uptake, and clinical outcomes should be reported systematically.

References

    1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.
    1. McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10:S21–S29.
    1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41. doi: 10.1111/j.1365-2893.2005.00651.x.
    1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–S46.
    1. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD. Hepatitis B and C virus infection among 1.2 Million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047–1055. doi: 10.1093/cid/cis616.
    1. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710–719.
    1. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755. doi: 10.1002/hep.23220.
    1. Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25:171–180. doi: 10.1017/S0266462309090229.
    1. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425–432. doi: 10.1136/gut.52.3.425.
    1. Dore GJ, Matthews GV, Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 2011;6:508–513. doi: 10.1097/COH.0b013e32834b87f8.
    1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444. doi: 10.1002/hep.24641.
    1. Friis RH, Sellers TH. Epidemiology for Public Health Practice. 4. Canada: Jones and Bartlett Publishers, LLC; 2009. Screening for Disease in the Community; pp. 409–436.
    1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47(No. RR-19):20–26.
    1. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep. 2009;58:1–166.
    1. Lucidarme D, Decoster A, Fremaux D, Harbonnier J, Jacob C, Vosgien V, Josse P, Villeger P, Henrio C, Prouvost-Keller B, Saccardy C, Lemaire M, Vazeille G, Duchene C, Thuillier M, Colbeaux C, Lefebvre AM, Forzy G, Filoche B. Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population. Gastroenterol Clin Biol. 2007;31:480–484. doi: 10.1016/S0399-8320(07)89415-2.
    1. Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, Preston FE, Watson HG, Wilde JT, Winter M. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia. 2001;7:339–345. doi: 10.1046/j.1365-2516.2001.00527.x.
    1. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR. 2009;58(No. RR-4):85–86. (No. RR-4)
    1. Vriend HJ, van Veen MG, Prins M, Urbanus AT, Boot HJ, Op de Coul ELM. Hepatitis C virus prevalence in the Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141(6):1310–1317. doi: 10.1017/S0950268812001884.
    1. Vrielink H, Reesink HW, van den Burg PJ, Zaaijer HL, Cuypers HT, Lelie PN, van der Poel CL. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion. 1997;37:845–849. doi: 10.1046/j.1537-2995.1997.37897424409.x.
    1. Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health. 2010;31:399–418. doi: 10.1146/annurev.publhealth.012809.103604.
    1. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992;15:350–353.
    1. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26:43S–47S. doi: 10.1002/hep.510260708.
    1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567. doi: 10.1016/S1473-3099(05)70216-4.
    1. Hao F. Prevalence of hepatitis C virus infection in pregnant women. Zhonghua Fu Chan Ke Za Zhi. 1993;28:668–702.
    1. Lu C. A seroepidemiological investigation on HCV infection among population in Tianjin area. Zhonghua Liu Xing Bing Xue Za Zhi. 1993;14:147–150.
    1. Fujimoto K, Momosaka Y, Uchida K, Ide H, Narisada H, Fujishiro K, Oda S, Okubo T. Implication of health checkups of students from developing countries in Japan. Nippon Koshu Eisei Zasshi. 1999;46:476–486.
    1. Fukui M. Natural history of HCV seropositive cases found in health screening. Hokkaido Igaku Zasshi. 1995;70:69–82.
    1. Imai Y, Tanaka H, Fukudai K, Zushi S, Yabuta T, Tujino A, Kurokawa M, Kono Y, Nishi K, Hayashi M. Present status of community-based HCV screening in Ikeda-Toyono Region, Osaka Prefecture, 2002. Acta Hepatologica Japonica. 2004;45:232–238. doi: 10.2957/kanzo.45.232.
    1. Ishizuka M. Economic evaluation of health care program for hepatitis C virus antibody screening. Nippon Koshu Eisei Zasshi. 1999;46:447–465.
    1. Kajikawa T, Katahira Y, Ohto M, Hara K, Umezono T, Saito M, Yoshikawa M, Sugiura N, Ebara M, Saisho H. Epidemiologic aspects of cases with positive HCV antibody and clinical features of hepatocellular carcinoma with positive HCV antibody based on mass survey in a rural area of Chiba prefecture. Acta Hepatologica Japonica. 1996;37:13–18. doi: 10.2957/kanzo.37.13.
    1. Kuroki T, Murai J, Fujino K, Ozaki S, Nakagishi M, Toukaiya M. The screening of hepatitis virus and its efficacy. Rinsho Byori. 1995;43:1095–1100.
    1. Michitaka K, Horiike N, Ohta Y. An epidemiological study of hepatitis C virus infection in a local district in Japan. Rinsho Byori. 1991;39:586–591.
    1. Watanabe Y, Machida K, Sato A, Ota S, Kiyosawa K. Survey for hepatitis in an isolated endemic area. Nippon Koshu Eisei Zasshi. 1996;43:989–996.
    1. Jonsdottir G, Briem H, Blondal T, Palsson G, Olafsson S, Gudnason T. Viral hepatitis B and C among immigrants in Iceland. Laeknabladid. 2006;92:669–673.
    1. Djeneva H, Aleksieva T. Screening of hepatitis markers for viral hepatitis B and C in healthy persons in the region of Stara Zagora. Bulg Med. 2003;11:6–8.
    1. Galetskii SA, Seniuta NB, Syrtsev AV, Abdullaev OM, Aliev DA, Kerimov AA, Yamashita M, Hayami M, Kato T, Mizokami M. Analysis of some viral infections, transmitted by parenteral and sexual routes, in the Republic of Azerbaijan. Vopr Virusol. 1999;44:232–236.
    1. Netesova IG, Iaroslavtseva OA, Dryga SA, Posukh OL, Osipova LP, Bronshtein EL, Zaitsev SA, Netesov SV. Frequency of encountering markers of viral hepatitis A, B, and C in the aboriginal inhabitants of the northwest region of Siberia. Vopr Virusol. 1995;40:172–174.
    1. Tagizadeh RK, Mammadov MK, Dadashova AE, Azimova AA. Infections caused by hepatitis virus B and C at inhabitants of Baku. Azerbaijan Med J. 2008;1:131–134.
    1. Ayvaz A, Nur N, Engin A, Cetinkaya S. Prevalence of hepatitis B and C in first grade primary school children living in Sivas, Turkey. Turk Pediatri Arsivi. 2010;45:132–136.
    1. Cagatay M, Tulek N, Koksalan H, Mert A. Prevalence of hepatitis C virus antibodies in hospital personnel. Mikrobiyol Bul. 1992;26:242–247.
    1. Pazdiora P, Topolcan O, Herynkova R. Hepatitis C antibodies in health personnel. Cesk Epidemiol Mikrobiol Imunol. 1994;43:29–31.
    1. Chen CJ, Lu SN, You SL, Wu MH, Wang LY, Lee LT, Huang GT, Yang PM, Lee HS. Community-based hepatocellular carcinoma screening in seven townships in Taiwan. J Formos Med Assoc. 1995;94(Suppl 2):S94–102.
    1. Tung W-C, Lu S-N, Wu M-H, Chen C-J. Screening of chronic active hepatitis from series of health examination database. J Intern Med Taiwan. 2004;15:65–75.
    1. Pauti MD, Simonnot N, Estecahandy P. Development of prevention programmes for HIV, hepatitis and sexually transmitted infections among migrants consulting in the doctors of the World French centers. Med Mal Infect. 2008;38:495–499. doi: 10.1016/j.medmal.2008.06.028.
    1. Pauti MD, Simonnot N, Estecahandy P. Development of actions for the prevention of HIV, hepatitis and Sexually Transmitted Infections among immigrants consulting in the Doctors of the World "Missions France". Med Mal Infect. 2009;39:191–195. doi: 10.1016/j.medmal.2008.12.004.
    1. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, Harris R, Ushiro-Lumb I, Moreea S, Alam S, Thomas HC, Khan S, Watt B, Pugh RN, Ramaiah S, Jervis R, Hughes A, Singhal S, Cameron S, Carman WF, Foster GR. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat. 2010;17:327–335. doi: 10.1111/j.1365-2893.2009.01240.x.
    1. Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, Wrobel VJ, Srishord M, Younossi ZM. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat. 2011;18(1):70–76. doi: 10.1111/j.1365-2893.2010.01278.x.
    1. Boyce DE, Tice AD, Ona FV, Akinaka KT, Lusk H. Viral hepatitis in a homeless shelter in Hawai'i. Hawaii Med J. 2009;68:113–115.
    1. Datta SD, Armstrong GL, Roome AJ, Alter MJ. Blood exposures and hepatitis C virus infections among emergency responders. Arch Intern Med. 2003;163:2605–2610. doi: 10.1001/archinte.163.21.2605.
    1. Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health. 2010;100(Suppl 1):S118–S124.
    1. Jimenez FP, Fuentes HM, Borbolla BE. Anti-HCV in patients transfused, in a health area attended by a family physician. Medical Office 19 de Abril. Acta Gastroenterol Latinoam. 2000;30:99–105.
    1. D'Souza RF, Glynn MJ, Alstead E, Foster GR, Ushiro-Lumb I. Improving hepatitis C services across the UK: response to a walk-in HCV testing service. Gut. 2004;53:1388.
    1. Trepka MJ, Zhang G, Leguen F, Obiaja K, Malow RM, De La Rosa M. Benefits and adverse effects of hepatitis C screening: early results of a screening program. J Public Health Manag Pract. 2007;13:263–269. doi: 10.1097/01.PHH.0000267684.23529.2c.
    1. Plard C, Shelly M, Millot J, Segouin C, Bertrand D, Le Divenah A. Anonymous and free screenings: population comparison between those conducted on-site in a testing centre and those done off-site. Sante Publique. 2007;19:355–362. doi: 10.3917/spub.075.0355.
    1. Meky FA, Stoszek SK, Abdel-Hamid M, Selim S, Abdel-Wahab A, Mikhail N, El-Kafrawy S, El-Daly M, Abdel-Aziz F, Sharaf S, Mohamed MK, Engle RE, Emerson SU, Purcell RH, Fix AD, Strickland GT. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis. 2006;42:628–633. doi: 10.1086/500133.
    1. Lu SN, Chen HC, Tang CM, Wu MH, Yu ML, Chuang WL, Lu CF, Chang WY, Chen CJ. Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. Pediatr Infect Dis J. 1998;17:142–145. doi: 10.1097/00006454-199802000-00012.
    1. Aslam M, Aslam J. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J Clin Gastroenterol. 2001;33:407–411. doi: 10.1097/00004836-200111000-00013.
    1. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148–155. doi: 10.1016/S0929-6646(09)60231-X.
    1. D'Souza G, Arafat R, Hwang L, Cunningham C, Shah S, Reynolds K. Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services' sexually transmitted disease clinics. J Viral Hepat. 2003;10:134–140. doi: 10.1046/j.1365-2893.2003.00410.x.
    1. Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D. Unselected hepatitis C screening of men who have sex with men attending sexual health clinics. J Infect. 2010;60:351–353. doi: 10.1016/j.jinf.2010.01.013.
    1. Weisbord JS, Trepka MJ, Zhang G, Smith IP, Brewer T. Prevalence of and risk factors for hepatitis C virus infection among STD clinic clientele in Miami, Florida. Sex Transm Infect. 2003;79:E1. doi: 10.1136/sti.79.1.e1.
    1. Gunn RA, Murray PJ, Brennan CH, Callahan DB, Alter MJ, Margolis HS. Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis. 2003;30:340–344. doi: 10.1097/00007435-200304000-00013.
    1. Mapagu MC, Martin SJ, Currie MJ, Bowden FJ. Screening for hepatitis C in sexual health clinic attendees. Sex Health. 2008;5:73–76. doi: 10.1071/SH07034.
    1. Zimmerman R, Finley C, Rabins C, McMahon K. Integrating viral hepatitis prevention into STD clinics in Illinois (excluding Chicago), 1999–2005. Public Health Rep. 2007;122(Suppl 2):18–23.
    1. Subiadur J, Harris JL, Rietmeijer CA. Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep. 2007;122(Suppl 2):12–17.
    1. Heseltine G, McFarlane J. Texas statewide hepatitis C counseling and testing, 2000–2005. Public Health Rep. 2007;122(Suppl 2):6–11.
    1. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis. 2001;28:166–170. doi: 10.1097/00007435-200103000-00008.
    1. Ellks R. Hepatitis C testing should be performed routinely in all patients attending sexual health services. Abstract for the 2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV Manchester United Kingdom. HIV Med. 2010;59
    1. Tweed E, Brant L, Hurrelle M, Klapper P, Ramsay M. Hepatitis C testing in sexual health services in England, 2002–7: results from sentinel surveillance. Sex Transm Infect. 2010;86:126–130. doi: 10.1136/sti.2009.036590.
    1. Monnet E, Mercet P, Woronoff-Lemsi MC, Bresson-Hadni S, Pruniaux J, Cottray P, Bouiller C, Allemand H, Miguet JP. Organized hepatitis C screening. Results and cost of a one-year campaign in a pilot area. Gastroenterol Clin Biol. 2000;24:541–546.
    1. Anderson EM, Mandeville RP, Hutchinson SJ, Cameron SO, Mills PR, Fox R, Ahmed S, Taylor A, Spence E, Goldberg DJ. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J. 2009;54:3–7.
    1. Ouzan D, Cavailler P, Hofliger P, Mamino C, Joly H, Tran A. Modalities of care in anti HCV positive patients identified in General Medicine in the Alpes-Maritimes district. Gastroenterol Clin Biol. 2003;27:376–380.
    1. Josset V, Torre JP, Tavolacci MP, Van Rossem-Magnani V, Anselme K, Merle V, Godart J, Libert A, Ladner J, Czernichow P. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol. 2004;28:351–357. doi: 10.1016/S0399-8320(04)94935-4.
    1. Pradat P, Caillat-Vallet E, Sahajian F, Bailly F, Excler G, Sepetjan M, Trepo C, Fabry J. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol. 2001;17:47–51. doi: 10.1023/A:1010902614443.
    1. Altman C, Lesiour A, Dunbavand A, Meyer L, de la Selle P, Buffet C. Screening of patients at risk for hepatitis C virus infection in general medicine. Gastroenterol Clin Biol. 1999;23:359–362.
    1. Helsper CW, van Essen GA, Bonten MJ, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010;27:328–332. doi: 10.1093/fampra/cmq006.
    1. Sahajian F, Excler G, Bailly F, Caillat-Vallet E, Trepo C, Sepetjan M, Fabry JY. Hepatitis C screening practices among private practitioners: impact of an information campaign. Gastroenterol Clin Biol. 2004;28:714–719. doi: 10.1016/S0399-8320(04)95061-0.
    1. Roudot-Thoraval F, Monnet E, Mercet P, Bastie A, Dhumeaux D, Miguet JP. Strategies of hepatitis C screening in general practice. Results of a two-center randomized trial. Gastroenterol Clin Biol. 2000;24:1037–1041.
    1. Groom H, Dieperink E, Nelson DB, Garrard J, Johnson JR, Ewing SL, Stockley H, Durfee J, Jonk Y, Willenbring ML, Ho SB. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol. 2008;42:97–106. doi: 10.1097/MCG.0b013e31802dc56f.
    1. Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol. 2008;103:131–137. doi: 10.1111/j.1572-0241.2007.01522.x.
    1. Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci. 2006;51:976–981. doi: 10.1007/s10620-006-9100-x.
    1. Rifai MA, Moles JK, Lehman LP, Van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics. 2006;47:112–121. doi: 10.1176/appi.psy.47.2.112.
    1. Zuniga IA, Chen JJ, Lane DS, Allmer J, Jimenez-Lucho VE. Analysis of a hepatitis C screening programme for US veterans. Epidemiol Infect. 2006;134:249–257.
    1. Alexanian AA, Oleszkiewicz GM, Al-Chalabi T, Atabani S, Muir D, Tudor-Williams G, Brown AS. Observational outcomes in a cohort of women identified as hepatitis C (HCV) antibody positive during routine antenatal clinic (ANC) screening. Abstract for the 60th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2009 Boston, MA United States. Hepatology. 2009;669A
    1. Abusheikha N, Akagbosu F, Marcus S, Lass A, Cousins C, Brinsden P. Viral screening and assisted conception treatment–the Bourn Hall experience. J Assist Reprod Genet. 1999;16:337–339. doi: 10.1023/A:1020414318129.
    1. Leikin EL, Reinus JF, Schmell E, Tejani N. Epidemiologic predictors of hepatitis C virus infection in pregnant women. Obstet Gynecol. 1994;84:529–534.
    1. Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut. 2000;47:277–280. doi: 10.1136/gut.47.2.277.
    1. Costa ZB, Machado GC, Avelino MM, Gomes FC, Macedo Filho JV, Minuzzi AL, Turchi MD, Stefani MM, de Souza WV, Martelli CM. Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil. BMC Infect Dis. 2009;9:116. doi: 10.1186/1471-2334-9-116.
    1. Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 2007;48:405–411. doi: 10.1176/appi.psy.48.5.405.
    1. Gunewardene R, Lampe L, Ilchef R. Prevalence of hepatitis C in two inpatient psychiatry populations. Australas Psychiatry. 2010;18:330–334. doi: 10.3109/10398561003763273.
    1. Lacey C, Ellen S, Devlin H, Wright E, Mijch A. Hepatitis C in psychiatry inpatients: testing rates, prevalence and risk behaviours. Australas Psychiatry. 2007;15:315–319. doi: 10.1080/10398560701358113.
    1. Capron D, Bensousan T, Darchis JP, Barbare JC, Butel J, Bental A, Cadranel JF, Goll A, Levy P, Ink O, Autret P, Bouraya D, Thiebaut JM, Moucheron JJ, Bernard M, Lallement PY, Delobel P. Hepatitis C virus infection risk factors in patients admitted in hospital emergency departments in Picardy. Value of oriented screening based on recommendations of the 'Direction Generale de la Sante'. Eur J Gastroenterol Hepatol. 1999;11:643–648. doi: 10.1097/00042737-199906000-00010.
    1. Alswaidi FM, O'Brien SS. Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening programme on the basis of their prevalence and transmission risk factors? J Epidemiol Community Health. 2009.
    1. Dubois F, Francois M, Mariotte N, Caces E, Vol S, Roingeard P, Barin F, Goudeau A, Tichet J. Serum alanine aminotransferase measurement as a guide to selective testing for hepatitis C during medical checkup. J Hepatol. 1994;21:837–841. doi: 10.1016/S0168-8278(94)80247-5.
    1. Roberts J, Cull M, Dean G, Richardson D, Fisher M. Improved but still suboptimal uptake of STI testing and vaccination in the outreach setting. Abstract for the 2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV Manchester United Kingdom. HIV Med. 2010;118
    1. Cohen DE, Russell CJ, Golub SA, Mayer KH. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care STDS. 2006;20:557–564. doi: 10.1089/apc.2006.20.557.
    1. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection. 2002;30:7–12. doi: 10.1007/s15010-001-1197-4.
    1. Tafuri S, Prato R, Martinelli D, Melpignano L, De Palma M, Quarto M, Germinario C. Prevalence of Hepatitis B, C, HIV and syphilis markers among refugees in Bari, Italy. BMC Infect Dis. 2010;10:213. doi: 10.1186/1471-2334-10-213.
    1. Sahajian F, Vanhems P, Bailly F, Fabry J, Trepo C, Sepetjan M. Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France. Eur J Public Health. 2007;17:263–271. doi: 10.1093/eurpub/ckl233.
    1. Sequist TD, Zaslavsky AM, Marshall R, Fletcher RH, Ayanian JZ. Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial. Arch Intern Med. 2009;169:364–371. doi: 10.1001/archinternmed.2008.564.
    1. Gollwitzer PM. Implementation Intentions: Strong effects of simple plans. Am Psychol. 1999;54:493–503.
    1. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR. 2003;52:(No. RR-3).
    1. Grimaudo NJ, Lado E. Hepatitis C screenings available at FNDC. Todays FDA. 2000;12:28–30.
    1. Wadley F. H.A.L.T. hepatitis C in Tennessee. Tenn Med. 1997;90:395.
    1. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008;215:33–42. doi: 10.1620/tjem.215.33.
    1. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259–1271. doi: 10.1093/cid/cis011.
    1. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263–270. doi: 10.7326/0003-4819-156-4-201202210-00378.
    1. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65:281–393.
    1. Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis M. A Systematic Review of the Effectiveness and Cost-Effectiveness of Interventions Aimed at Raising Awareness and Engaging with Groups who are at an Increased Risk of Hepatitis B and C Infection - Final Report. Liverpool: Liverpool John Moores University; 2012. (Centre for Public Health, Faculty of Health and Applied Social Sciences).
    1. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817–822. doi: 10.7326/0003-4819-157-9-201211060-00529.
    1. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, Kashiwagi S. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol. 1995;90:794–799.
    1. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group. Hepatology. 1996;24:979–986.
    1. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442–1449. doi: 10.1002/hep.1840200611.
    1. Fagundes GD, Bonazza V, Ceretta LB, Back AJ, Bettiol J. Detection of the hepatitis C virus in a population of adults. Rev Lat Am Enfermagem. 2008;16:396–400.
    1. Batash S, Khaykis I, Raicht RF, Bini EJ. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol. 2008;103:922–927. doi: 10.1111/j.1572-0241.2008.01789.x.
    1. ARèS 92. Intérêt d'un "parcours santé" proposé aux résidents d'un foyer Sonacotra. BEH. 2004;43:205–206.
    1. Goetz AM, Ndimbie OK, Wagener MM, Muder RR. Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center. Transplant. 1995;59:990–994. doi: 10.1097/00007890-199504150-00012.
    1. Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E Jr, Quinn TC. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med. 1993;153:1705–1712. doi: 10.1001/archinte.1993.00410140095011.
    1. Panlilio AL, Shapiro CN, Schable CA, Mendelson MH, Montecalvo MA, Kunches LM, Perry SW 3rd, Edwards JR, Srivastava PU, Culver DH. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg. 1995;180:16–24.
    1. Upfal MJ, Naylor P, Mutchnick MM. Hepatitis C screening and prevalence among urban public safety workers. J Occup Environ Med. 2001;43:402–411. doi: 10.1097/00043764-200104000-00019.
    1. Gershon RR, Vlahov D, Farzadegan H, Alter MJ. Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland. Infect Control Hosp Epidemiol. 1995;16:194–197. doi: 10.2307/30140977.
    1. Torda AJ. Vaccination and screening of medical students: results of a student health initiative. Med J Aust. 2008;189:484–486.
    1. Arumainayagam J, Grimshaw R, Acharya S, Chandramani S, Morrall IA, Pugh RN. Value of targeting at-risk populations at outreach venues: Findings from a local sauna. Int J STD AIDS. 2009;20:642–643. doi: 10.1258/ijsa.2008.008424.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj